TRAX

NASDAQ

First Tracks Biotherapeutics

$32.40
+11.63 (+55.99%)
2026-07-09 00:00
Healthcare Biotechnology
-- --

Short Interest (1 Year)

% of Volume Sold Short
Market Cap
N/A
P/E Ratio
N/A
52W Low 52W High
$11.30 $33.70
Volume
4.5M

About First Tracks Biotherapeutics

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifical...

Employees 104

Financial Highlights

Annual Quarterly
Year Revenue Op Margin Net Income Free Cash Flow
2025 N/A N/A% -$166.1M -$142.8M
2024 N/A N/A% -$163.7M -$125.4M
2023 N/A N/A% -$106.2M -$92.2M
View Full Financial Statements